一种NSAIDs的子集可以独立于循环氧基因酶活性来降低氨基胺基的Abeta42
1Department of Neurosciences, University of California San Diego, La Jolla, California 92093, USA.
Nature
|November 9, 2001
概括
非类固醇抗炎药物 (NSAIDs) 显著降低粉样β 42 (Abeta42) 水平,这是阿尔茨海默病的关键因素. 这种Abeta42降低发生在循环氧化酶抑制的独立性,这表明一种新的治疗途径.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 分子生物学分子生物学
背景情况:
- 流行病学研究表明,非类固醇抗炎药物 (NSAIDs) 可能会降低阿尔茨海默病的患病率.
- 拟议的机制涉及NSAIDs降低神经毒性炎症大脑反应,但这仍然未被证明.
研究的目的:
- 调查NSAIDs对粉样β产生的直接影响.
- 确定NSAID是否降低了高度氨基原的Abeta42,并阐明了潜在的机制.
主要方法:
- 用各种NSAID (ibuprofen,indomethacin,sulindac sulphide) 治疗培养细胞和突变β-粉样蛋白前体蛋白 (APP) 转基因小鼠.
- 量化阿贝塔42和其他阿贝塔异型 (例如,阿贝塔1-38).
- 评估循环氧化酶 (COX) 活性和Notch裂纹.
主要成果:
- 在培养细胞中,布洛芬,印米他素和硫酸硫化物降低了阿贝塔42的产量高达80%.
- 这种Abeta42的降低观察到独立于COX抑制.
- 给小鼠服用布洛芬降低了大脑Abeta42水平.
- 观察到阿贝塔1-38的同时增加,这表明微妙的玛分泌酶调节.
结论:
- 无 NSAID 通过降低 Abeta42 水平,直接减少粉样蛋白病理.
- 降低Abeta42的效果是独立于COX活性.
- 这种机制为阿尔茨海默病提供了潜在的治疗策略,通过向致病性阿贝塔42物种.
相关概念视频
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Antihypertensive Drugs: Angiotensin II Receptor Blockers
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Antihypertensive Drugs: Direct Renin Inhibitors
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists
Histamine H2 receptors, which are intricately located on the basolateral membrane of parietal cells, play a crucial role in modulating gastric acid secretion. When released from enterochromaffin-like cells, histamine engages H2 receptors, initiating the cyclic AMP (cAMP) pathway. In this pathway, adenylyl cyclase converts ATP into cAMP, elevating intracellular cAMP levels. The activation of protein kinase A follows, stimulating the proton pump. This stimulation prompts the secretion of hydrogen...


